Both of the listed companies that sell mainly to American police departments raised their guidance in August, and both have been marked down hard since. Axon Enterprise, which sells TASER conducted-energy weapons, body cameras and the Axon Evidence cloud that stores the footage, has lost 40.1% of its value over twelve months. Cadre Holdings, which makes Safariland body armor, duty gear and Med-Eng bomb suits for police, corrections and federal agencies, is down 28.3%.

The tidy explanation is their shared paymaster. Neither company has a commercial customer of consequence; every dollar either earns is appropriated by a city council, a statehouse or Congress. If that dollar is tightening, both equities deserve less regardless of what they shipped last quarter. So the question is whether the squeeze is visible where it would appear first — in orders.

The buyer is genuinely tight

The National Association of State Budget Officers' spring survey put median general-fund spending growth across the states at 0.6% for fiscal 2027 against 2.5% median revenue growth, with thirteen states reporting $26.3bn of projected gaps before balancing measures. Federally, the fiscal 2027 request would cut the Office of Justice Programs' State and Local Law Enforcement Assistance account to $1.619bn, $781m below fiscal 2026, trim Byrne Justice Assistance Grant formula money by 9% and cut the COPS school violence prevention program by a third — the exact channels through which a small department buys vests and camera subscriptions. Cutting the other way, the Justice Department is readying up to $3.5bn in law-enforcement grants. The money is being reshuffled more than withdrawn.

Neither order book shows it

Axon is paid on ten-year bundled Officer Safety Plans, so a budget shock reaches its revenue line late and its bookings early. Bookings accelerated. "Future contracted bookings grew more than 40% year over year to $15.1 billion, reflecting the broad-based momentum across products and end markets," chief executive Rick Smith told investors on August 5. Annual recurring revenue reached $1.6bn, up 39%, with net revenue retention of 126%. Second-quarter revenue of $904.4m grew 35.3%, a tenth consecutive quarter above 30%, and Axon raised full-year guidance to growth of 32-34% from 30-32%.

Cadre sells the least discretionary thing in the ledger — a vest replaced on a cycle — and its backlog reached a record $368m, a second straight record, helped by a $61m indefinite-delivery contract with the Federal Bureau of Investigation for ballistic panels and a $50m Med-Eng award. Guidance went up too, to $749m-$769m of sales from $736m-$758m, and the $0.10 quarterly dividend was maintained. The nearest thing to a warning from either company was Cadre's call commentary about a growing focus on balancing state and local budgets.

Where the two part company

Cadre's de-rating is written by its own income statement. Only 5% of its 32% second-quarter growth was organic, the rest bought with TYR Tactical, closed in January; full-year organic growth is guided to 3-5%. Net income of $11.4m fell 6.6% on that 31.8% revenue gain, after a first quarter in which gross margin dropped to 37.7% from 42.4%. Consensus has 2026 earnings of $1.00 a share against $1.02 last year — 21% more revenue, no more profit, as acquisition debt and intangible amortization absorb it. Bank of America moved to Underperform on August 13 with a $26 target; the shares closed at $26.06 on Monday. At 26.0x forward, against roughly 36x a year ago and 16.2x trailing enterprise value to EBITDA, the reset matches the arithmetic; a 7.0% trailing free-cash-flow yield is the argument against it.

Axon's month was two sessions and two events. The shares fell 11.4% on September 1 and 9.8% on September 15, the day it announced a zero-coupon convertible that priced at $1.15bn including the over-allotment, due 2031, convertible near $652 against a stock now around $425. Two days after a September 23 Senate Judiciary subcommittee hearing on automatic license-plate-reader surveillance — Axon was invited, did not appear, and was told subpoenas were possible — Goldman Sachs cut its target to $675. Axon now trades at 55.1x forward earnings against 171.1x trailing and a reported five-year average forward multiple near 78x; Motorola Solutions, the closest public-safety comparable, is at 25.5x forward on 13.3% growth, which makes Axon the cheaper of the two per point of growth. An 80.6x trailing EV/EBITDA and a 0.39% free-cash-flow yield are what the bear owns.

So the shared-customer story is real in statehouses and invisible in both order books, and the two stocks fell for unrelated reasons: Cadre because a consumable business bought its growth and is paying for it, Axon because a very expensive multiple met dilution and a subpoena threat in the same month. An appropriation deferred one year reappears the next. A hearing that decides what a camera network may record does not, and Axon has not yet sat down at it.